Product logins

Find logins to all Clarivate products below.


Clarivate Epidemiology’s coverage of type 2 diabetes (T2D) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of T2D for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s T2D forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people living with T2D?
  • Of all people with T2D, how many in each country have been formally diagnosed?
  • Of all people diagnosed with T2D, how many in the major pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of T2D over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 36 T2D patient populations, including the following:

  • Total prevalent cases.
  • Diagnosed prevalent cases.
  • Diagnosed drug-treated prevalent cases.
  • Diagnosed drug-treated controlled prevalent cases.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…
Report
Type 2 Diabetes – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Metformin remains the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. More effective, safer, and…
Report
Ocular Pain – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of ocular pain comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy…
Report
Type 1 Diabetes – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment options for type 1 diabetes (T1D) patients are limited; insulins, pramlintide (in the United States), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors (only in Japan) are the…
Report
Ulcerative Colitis – Epidemiology – Epidemiology – Ulcerative Colitis – Mature Markets
Clarivate Epidemiology’s coverage of ulcerative colitis (UC) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…